Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis

Isao Ito, Yukio Yuzawa, Masashi Mizuno, Kazuhiro Nishikawa, Akira Tashita, Takahito Jomori, Nigishi Hotta, Seiichi Matsuo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In an attempt to explore a novel therapeutic approach, a new synthetic sulfatide derivative (SKK60037) was evaluated in an acute rat model of P-selectin and leukocyte-dependent thrombotic glomerulonephritis (TG). In vitro, SKK60037 inhibits the function of P- and L-selectin more effectively than sialyl Lewis X (sLex), a well-established selectin blocker. TG was induced by the intravenous administration of nephrotoxic globulin (NTG) to rats pretreated with a subclinical dose of lipopolysaccharide. In this model, platelet accumulation was remarkable within 10 minutes after induction of disease, followed by the infiltration of leukocytes, mainly neutrophils and macrophages. Thrombus formation and fibrinogen deposition in the glomeruli were observed within 1 hour, and they proceeded until 6 hours. P-selectin was highly expressed in glomeruli, whereas E-selectin and L-selectin ligands were not detected. We tested the effects of SKK60037 in this model in comparison with sLex and antirat P-selectin monoclonal antibody (ARP2-4). SKK60037 blocked platelet accumulation in glomerular capillaries at 10 minutes after NTG injection. At 6 hours, leukocyte infiltration and thrombosis were significantly suppressed. Protective effects of SKK60037 were similar to those of ARP2-4, whereas sLex showed minimum effect. The superior effects and more favorable characteristics of SKK60037 to sLex suggest the potential of SKK60037 for clinical application.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume38
Issue number2
DOIs
Publication statusPublished - 01-01-2001
Externally publishedYes

Fingerprint

Selectins
Glomerulonephritis
P-Selectin
L-Selectin
Leukocytes
Globulins
Thrombosis
Blood Platelets
Sulfoglycosphingolipids
E-Selectin
SKK60037
Intravenous Administration
Fibrinogen
Lipopolysaccharides
Neutrophils
Macrophages
Monoclonal Antibodies
Ligands
Injections

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Ito, Isao ; Yuzawa, Yukio ; Mizuno, Masashi ; Nishikawa, Kazuhiro ; Tashita, Akira ; Jomori, Takahito ; Hotta, Nigishi ; Matsuo, Seiichi. / Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. In: American Journal of Kidney Diseases. 2001 ; Vol. 38, No. 2. pp. 265-273.
@article{1e01cdfa8b81493aa8ce0d0a5e672316,
title = "Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis",
abstract = "In an attempt to explore a novel therapeutic approach, a new synthetic sulfatide derivative (SKK60037) was evaluated in an acute rat model of P-selectin and leukocyte-dependent thrombotic glomerulonephritis (TG). In vitro, SKK60037 inhibits the function of P- and L-selectin more effectively than sialyl Lewis X (sLex), a well-established selectin blocker. TG was induced by the intravenous administration of nephrotoxic globulin (NTG) to rats pretreated with a subclinical dose of lipopolysaccharide. In this model, platelet accumulation was remarkable within 10 minutes after induction of disease, followed by the infiltration of leukocytes, mainly neutrophils and macrophages. Thrombus formation and fibrinogen deposition in the glomeruli were observed within 1 hour, and they proceeded until 6 hours. P-selectin was highly expressed in glomeruli, whereas E-selectin and L-selectin ligands were not detected. We tested the effects of SKK60037 in this model in comparison with sLex and antirat P-selectin monoclonal antibody (ARP2-4). SKK60037 blocked platelet accumulation in glomerular capillaries at 10 minutes after NTG injection. At 6 hours, leukocyte infiltration and thrombosis were significantly suppressed. Protective effects of SKK60037 were similar to those of ARP2-4, whereas sLex showed minimum effect. The superior effects and more favorable characteristics of SKK60037 to sLex suggest the potential of SKK60037 for clinical application.",
author = "Isao Ito and Yukio Yuzawa and Masashi Mizuno and Kazuhiro Nishikawa and Akira Tashita and Takahito Jomori and Nigishi Hotta and Seiichi Matsuo",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/ajkd.2001.26085",
language = "English",
volume = "38",
pages = "265--273",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Ito, I, Yuzawa, Y, Mizuno, M, Nishikawa, K, Tashita, A, Jomori, T, Hotta, N & Matsuo, S 2001, 'Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis', American Journal of Kidney Diseases, vol. 38, no. 2, pp. 265-273. https://doi.org/10.1053/ajkd.2001.26085

Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. / Ito, Isao; Yuzawa, Yukio; Mizuno, Masashi; Nishikawa, Kazuhiro; Tashita, Akira; Jomori, Takahito; Hotta, Nigishi; Matsuo, Seiichi.

In: American Journal of Kidney Diseases, Vol. 38, No. 2, 01.01.2001, p. 265-273.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis

AU - Ito, Isao

AU - Yuzawa, Yukio

AU - Mizuno, Masashi

AU - Nishikawa, Kazuhiro

AU - Tashita, Akira

AU - Jomori, Takahito

AU - Hotta, Nigishi

AU - Matsuo, Seiichi

PY - 2001/1/1

Y1 - 2001/1/1

N2 - In an attempt to explore a novel therapeutic approach, a new synthetic sulfatide derivative (SKK60037) was evaluated in an acute rat model of P-selectin and leukocyte-dependent thrombotic glomerulonephritis (TG). In vitro, SKK60037 inhibits the function of P- and L-selectin more effectively than sialyl Lewis X (sLex), a well-established selectin blocker. TG was induced by the intravenous administration of nephrotoxic globulin (NTG) to rats pretreated with a subclinical dose of lipopolysaccharide. In this model, platelet accumulation was remarkable within 10 minutes after induction of disease, followed by the infiltration of leukocytes, mainly neutrophils and macrophages. Thrombus formation and fibrinogen deposition in the glomeruli were observed within 1 hour, and they proceeded until 6 hours. P-selectin was highly expressed in glomeruli, whereas E-selectin and L-selectin ligands were not detected. We tested the effects of SKK60037 in this model in comparison with sLex and antirat P-selectin monoclonal antibody (ARP2-4). SKK60037 blocked platelet accumulation in glomerular capillaries at 10 minutes after NTG injection. At 6 hours, leukocyte infiltration and thrombosis were significantly suppressed. Protective effects of SKK60037 were similar to those of ARP2-4, whereas sLex showed minimum effect. The superior effects and more favorable characteristics of SKK60037 to sLex suggest the potential of SKK60037 for clinical application.

AB - In an attempt to explore a novel therapeutic approach, a new synthetic sulfatide derivative (SKK60037) was evaluated in an acute rat model of P-selectin and leukocyte-dependent thrombotic glomerulonephritis (TG). In vitro, SKK60037 inhibits the function of P- and L-selectin more effectively than sialyl Lewis X (sLex), a well-established selectin blocker. TG was induced by the intravenous administration of nephrotoxic globulin (NTG) to rats pretreated with a subclinical dose of lipopolysaccharide. In this model, platelet accumulation was remarkable within 10 minutes after induction of disease, followed by the infiltration of leukocytes, mainly neutrophils and macrophages. Thrombus formation and fibrinogen deposition in the glomeruli were observed within 1 hour, and they proceeded until 6 hours. P-selectin was highly expressed in glomeruli, whereas E-selectin and L-selectin ligands were not detected. We tested the effects of SKK60037 in this model in comparison with sLex and antirat P-selectin monoclonal antibody (ARP2-4). SKK60037 blocked platelet accumulation in glomerular capillaries at 10 minutes after NTG injection. At 6 hours, leukocyte infiltration and thrombosis were significantly suppressed. Protective effects of SKK60037 were similar to those of ARP2-4, whereas sLex showed minimum effect. The superior effects and more favorable characteristics of SKK60037 to sLex suggest the potential of SKK60037 for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0034909732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909732&partnerID=8YFLogxK

U2 - 10.1053/ajkd.2001.26085

DO - 10.1053/ajkd.2001.26085

M3 - Article

VL - 38

SP - 265

EP - 273

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -